Moises A Huaman1, Timothy R Sterling2, Bryan E Shepherd3, Christina T Fiske4. 1. Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, TN, USA; Vanderbilt Tuberculosis Center, Vanderbilt University School of Medicine, Nashville, TN, USA. Electronic address: moises.huaman@uky.edu. 2. Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, TN, USA; Vanderbilt Tuberculosis Center, Vanderbilt University School of Medicine, Nashville, TN, USA. Electronic address: timothy.sterling@vanderbilt.edu. 3. Vanderbilt Tuberculosis Center, Vanderbilt University School of Medicine, Nashville, TN, USA; Department of Biostatistics, Vanderbilt University, Nashville, TN, USA. Electronic address: bryan.shepherd@vanderbilt.edu. 4. Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, TN, USA; Vanderbilt Tuberculosis Center, Vanderbilt University School of Medicine, Nashville, TN, USA. Electronic address: christina.fiske@vanderbilt.edu.
Abstract
OBJECTIVE: 25-Hydroxyvitamin D [25(OH)D] levels after recovery from tuberculosis (TB) may reflect pre-morbid levels and therefore provide insight into pathogenesis. We assessed 25(OH)D levels after recovery from TB disease, and compared to levels in persons without TB disease. METHODS: Case-control study. Cases were persons who had recovered from culture-confirmed Mycobacterium tuberculosis disease. Controls were persons without TB disease. Total 25(OH)D was measured from stored plasma specimens using liquid chromatography-mass spectrometry. RESULTS: 29 persons with prior TB disease and 36 controls were included. Median 25(OH)D levels were 24.7 ng/mL (IQR, 18.3-34.1) in prior TB disease, and 33.6 ng/mL (IQR, 26.2-42.4) in controls (Mann-Whitney; P = 0.01). Multivariable linear regression analysis showed that black race (adjusted mean difference [β] = -8.3 ng/mL; 95% CI -14.5, -2.2; P < 0.01), enrollment in winter (β = -10.4 ng/mL; 95% CI -17.0, -3.8; P < 0.01) and prior TB disease (β = -5.8 ng/mL; 95% CI -11.4, -0.3; P = 0.05) were associated with lower 25(OH)D levels. CONCLUSIONS: Persons who had recovered from TB disease had lower 25(OH)D levels compared to controls without TB disease, after adjusting for important confounders. Larger, longitudinal studies are needed to further characterize the possible role of low 25(OH)D in the pathogenesis of TB disease and TB recurrence after recovery.
OBJECTIVE:25-Hydroxyvitamin D [25(OH)D] levels after recovery from tuberculosis (TB) may reflect pre-morbid levels and therefore provide insight into pathogenesis. We assessed 25(OH)D levels after recovery from TB disease, and compared to levels in persons without TB disease. METHODS: Case-control study. Cases were persons who had recovered from culture-confirmed Mycobacterium tuberculosis disease. Controls were persons without TB disease. Total 25(OH)D was measured from stored plasma specimens using liquid chromatography-mass spectrometry. RESULTS: 29 persons with prior TB disease and 36 controls were included. Median 25(OH)D levels were 24.7 ng/mL (IQR, 18.3-34.1) in prior TB disease, and 33.6 ng/mL (IQR, 26.2-42.4) in controls (Mann-Whitney; P = 0.01). Multivariable linear regression analysis showed that black race (adjusted mean difference [β] = -8.3 ng/mL; 95% CI -14.5, -2.2; P < 0.01), enrollment in winter (β = -10.4 ng/mL; 95% CI -17.0, -3.8; P < 0.01) and prior TB disease (β = -5.8 ng/mL; 95% CI -11.4, -0.3; P = 0.05) were associated with lower 25(OH)D levels. CONCLUSIONS:Persons who had recovered from TB disease had lower 25(OH)D levels compared to controls without TB disease, after adjusting for important confounders. Larger, longitudinal studies are needed to further characterize the possible role of low 25(OH)D in the pathogenesis of TB disease and TB recurrence after recovery.
Authors: Paulo R Z Antas; Li Ding; Judith Hackman; Linda Reeves-Hammock; Ayumi K Shintani; Joshua Schiffer; Steven M Holland; Timothy R Sterling Journal: J Allergy Clin Immunol Date: 2006-04 Impact factor: 10.793
Authors: Philip T Liu; Steffen Stenger; Huiying Li; Linda Wenzel; Belinda H Tan; Stephan R Krutzik; Maria Teresa Ochoa; Jürgen Schauber; Kent Wu; Christoph Meinken; Diane L Kamen; Manfred Wagner; Robert Bals; Andreas Steinmeyer; Ulrich Zügel; Richard L Gallo; David Eisenberg; Martin Hewison; Bruce W Hollis; John S Adams; Barry R Bloom; Robert L Modlin Journal: Science Date: 2006-02-23 Impact factor: 47.728
Authors: R J Wilkinson; M Llewelyn; Z Toossi; P Patel; G Pasvol; A Lalvani; D Wright; M Latif; R N Davidson Journal: Lancet Date: 2000-02-19 Impact factor: 79.321
Authors: M J Brodie; A R Boobis; C J Hillyard; G Abeyasekera; J C Stevenson; I MacIntyre; B K Park Journal: Clin Pharmacol Ther Date: 1982-10 Impact factor: 6.875
Authors: G Vanham; K Edmonds; L Qing; D Hom; Z Toossi; B Jones; C L Daley; B Huebner; L Kestens; P Gigase; J J Ellner Journal: Clin Exp Immunol Date: 1996-01 Impact factor: 4.330
Authors: Caian L Vinhaes; Deivide Oliveira-de-Souza; Paulo S Silveira-Mattos; Betania Nogueira; Ruiru Shi; Wang Wei; Xing Yuan; Guolong Zhang; Ying Cai; Clifton E Barry; Laura E Via; Kiyoshi F Fukutani; Bruno B Andrade; Katrin D Mayer-Barber Journal: Cytokine Date: 2019-06-18 Impact factor: 3.861
Authors: Christina T Fiske; Amondrea Blackman; Fernanda Maruri; Peter F Rebeiro; Moises Huaman; Jamie Kator; Holly M Scott Algood; Timothy R Sterling Journal: BMC Infect Dis Date: 2019-04-30 Impact factor: 3.090